Cabozantinib (BioDeep_00000858445)
代谢物信息卡片
Cabozantinib (XL184, BMS-907351)
化学式: C28H24FN3O5 (501.1699906)
中文名称: 卡博替尼
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F
InChI: InChI=1S/C28H24FN3O5/c1-35-24-15-21-22(16-25(24)36-2)30-14-11-23(21)37-20-9-7-19(8-10-20)32-27(34)28(12-13-28)26(33)31-18-5-3-17(29)4-6-18/h3-11,14-16H,12-13H2,1-2H3,(H,31,33)(H,32,34)
描述信息
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors
C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor > C93259 - VEGFR Tyrosine Kinase Inhibitor
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C164000 - c-Met-targeting Agent
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163953 - VEGFR-targeting Agent
C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor
C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C159438 - RET Inhibitor
同义名列表
2 个代谢物同义名
数据库引用编号
6 个数据库交叉引用编号
- ChEBI: CHEBI:72317
- KEGGdrug: D10062
- PubChem: 25102847
- DrugBank: DB08875
- ChEMBL: CHEMBL2105717
- CAS: 849217-68-1
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Jingyang Su, Cui Ni, Yuqian Wu, Jialin Zhang, Zelin Cai, Jinhua Lu, Shengyou Lin, Jue Wang. Comparative efficacy and safety of cabozantinib for malignant tumors: a systematic review and meta-analysis.
Expert review of anticancer therapy.
2024 May; 24(5):293-302. doi:
10.1080/14737140.2024.2337266. [PMID: 38551185] - Hiroyuki Suzuki, Hideki Iwamoto, Toshimitsu Tanaka, Takahiko Sakaue, Yasuko Imamura, Atsutaka Masuda, Toru Nakamura, Hironori Koga, Yujin Hoshida, Takumi Kawaguchi. Fibroblast growth factor inhibition by molecular-targeted agents mitigates immunosuppressive tissue microenvironment in hepatocellular carcinoma.
Hepatology international.
2024 Apr; 18(2):610-622. doi:
10.1007/s12072-023-10603-z. [PMID: 37864726] - Xianhua She, Donghong Yin, Qian Guo, Yang Tang, Shuyun Wang, Xuyan Wang. Electrolyte disorders induced by six multikinase inhibitors therapy for renal cell carcinoma: a large-scale pharmacovigilance analysis.
Scientific reports.
2024 03; 14(1):5592. doi:
10.1038/s41598-024-56335-4. [PMID: 38454105] - Yang Zhou, Shuang Xiang, Fang Yang, Xiaoyun Lu. Targeting Gatekeeper Mutations for Kinase Drug Discovery.
Journal of medicinal chemistry.
2022 12; 65(23):15540-15558. doi:
10.1021/acs.jmedchem.2c01361. [PMID: 36395392] - Shingpan Chan, Yunong Zhang, Jie Wang, Qiuchun Yu, Xia Peng, Jian Zou, Licheng Zhou, Li Tan, Yunxin Duan, Yang Zhou, Hoon Hur, Jing Ai, Zhen Wang, Xiaomei Ren, Zhang Zhang, Ke Ding. Discovery of 3-Aminopyrazole Derivatives as New Potent and Orally Bioavailable AXL Inhibitors.
Journal of medicinal chemistry.
2022 11; 65(22):15374-15390. doi:
10.1021/acs.jmedchem.2c01346. [PMID: 36358010] - Binyong Liang, Haichuan Wang, Yu Qiao, Xue Wang, Manning Qian, Xinhua Song, Yi Zhou, Yi Zhang, Runze Shang, Li Che, Yifa Chen, Zhiyong Huang, Hong Wu, Satdarshan P Monga, Yong Zeng, Diego F Calvisi, Xiaoping Chen, Xin Chen. Differential requirement of Hippo cascade during CTNNB1 or AXIN1 mutation-driven hepatocarcinogenesis.
Hepatology (Baltimore, Md.).
2022 Aug; ?(?):. doi:
10.1002/hep.32693. [PMID: 35921500] - Ruizhe Liu, Kaifeng Qiu, Junyan Wu, Yanqing Jiang, Peihao Wu, Jianxin Pang. Cost-effectiveness analysis of nivolumab plus cabozantinib versus sunitinib as first-line therapy in advanced renal cell carcinoma.
Immunotherapy.
2022 Aug; 14(11):859-869. doi:
10.2217/imt-2021-0156. [PMID: 35754404] - Chung-Han Lee, Martin H Voss, Maria Isabel Carlo, Ying-Bei Chen, Mark Zucker, Andrea Knezevic, Robert A Lefkowitz, Natalie Shapnik, Chloe Dadoun, Ed Reznik, Neil J Shah, Colette Ngozi Owens, Deaglan Joseph McHugh, David Henry Aggen, Andrew Leonard Laccetti, Ritesh Kotecha, Darren R Feldman, Robert J Motzer. Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non-Clear-Cell Renal Cell Carcinoma and Genomic Correlates.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2022 Jul; 40(21):2333-2341. doi:
10.1200/jco.21.01944. [PMID: 35298296] - Edwin Choy, Gregory M Cote, M Dror Michaelson, Lori Wirth, Justin F Gainor, Alona Muzikansky, Lecia V Sequist, Ryan J Sullivan, Panagiotis M Fidias, Alice Shaw, Rebecca S Heist. Phase II Study of Cabozantinib in Patients With Bone Metastasis.
The oncologist.
2022 Jul; 27(7):600-606. doi:
10.1093/oncolo/oyac083. [PMID: 35524758] - Fatemeh Aghai-Trommeschlaeger, Sebastian Zimmermann, Anja Gesierich, Charis Kalogirou, Maria-Elisabeth Goebeler, Pius Jung, Theo Pelzer, Max Kurlbaum, Hartwig Klinker, Nora Isberner, Oliver Scherf-Clavel. Comparison of a newly developed high performance liquid chromatography method with diode array detection to a liquid chromatography tandem mass spectrometry method for the quantification of cabozantinib, dabrafenib, nilotinib and osimertinib in human serum - Application to therapeutic drug monitoring.
Clinical biochemistry.
2022 Jul; 105-106(?):35-43. doi:
10.1016/j.clinbiochem.2022.04.011. [PMID: 35483452] - Daniel M Geynisman, Mauricio Burotto, Camillo Porta, Cristina Suarez, Maria T Bourlon, Stephen Huo, Viviana Del Tejo, Ella X Du, Xiaoran Yang, Keith A Betts, Toni K Choueiri, Bradley McGregor. Temporal Trends in Grade 3/4 Adverse Events and Associated Costs of Nivolumab Plus Cabozantinib Versus Sunitinib for Previously Untreated Advanced Renal Cell Carcinoma.
Clinical drug investigation.
2022 Jul; 42(7):611-622. doi:
10.1007/s40261-022-01170-6. [PMID: 35696045] - Robert J Motzer, Thomas Powles, Mauricio Burotto, Bernard Escudier, Maria T Bourlon, Amishi Y Shah, Cristina Suárez, Alketa Hamzaj, Camillo Porta, Christopher M Hocking, Elizabeth R Kessler, Howard Gurney, Yoshihiko Tomita, Jens Bedke, Joshua Zhang, Burcin Simsek, Christian Scheffold, Andrea B Apolo, Toni K Choueiri. Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial.
The Lancet. Oncology.
2022 07; 23(7):888-898. doi:
10.1016/s1470-2045(22)00290-x. [PMID: 35688173] - Francisco Javier Melgosa Ramos, Andrea Estebánez Corrales, Almudena Mateu Puchades. Hand ulcers and cutaneous leucocytoclastic vasculitis secondary to cabozantinib treatment for renal cell carcinoma.
Medicina clinica.
2022 06; 158(11):e4-e5. doi:
10.1016/j.medcli.2021.09.024. [PMID: 34895893] - Hidekazu Tachibana, Toru Inakawa, Yuki Nemoto, Hiroki Ishihara, Hironori Fukuda, Kazuhiko Yoshida, Junpei Iizuka, Yasunobu Hashimoto, Kazunari Tanabe, Tsunenori Kondo, Toshio Takagi. Efficacy of Cabozantinib for Papillary Compared With Clear-cell Renal Cell Carcinoma Following Immune Checkpoint Inhibitor Treatment.
Anticancer research.
2022 Jun; 42(6):3151-3158. doi:
10.21873/anticanres.15804. [PMID: 35641290] - Giuseppe Procopio, Pierangela Sepe, Melanie Claps, Sebastiano Buti, Maurizio Colecchia, Patrizia Giannatempo, Valentina Guadalupi, Luigi Mariani, Luca Lalli, Giovanni Fucà, Filippo de Braud, Elena Verzoni. Cabozantinib as First-line Treatment in Patients With Metastatic Collecting Duct Renal Cell Carcinoma: Results of the BONSAI Trial for the Italian Network for Research in Urologic-Oncology (Meet-URO 2 Study).
JAMA oncology.
2022 06; 8(6):910-913. doi:
10.1001/jamaoncol.2022.0238. [PMID: 35420628] - Matteo Santoni, Gaetano Aurilio, Francesco Massari, Enrique Grande, Marc R Matrana, Mimma Rizzo, Ugo De Giorgi, Lorena Incorvaia, Angelo Martignetti, Javier Molina-Cerrillo, Ignacio Ortego Zabalza, Veronica Mollica, Alessandro Rizzo, Nicola Battelli, Camillo Porta. Nivolumab VERSUS Cabozantinib as Second-Line Therapy in Patients With Advanced Renal Cell Carcinoma: A Real-World Comparison.
Clinical genitourinary cancer.
2022 06; 20(3):285-295. doi:
10.1016/j.clgc.2022.02.003. [PMID: 35305916] - Kuan-Wei Su, Da-Liang Ou, Yu-Hsuan Fu, Hwei-Fang Tien, Hsin-An Hou, Liang-In Lin. Repurposing cabozantinib with therapeutic potential in KIT-driven t(8;21) acute myeloid leukaemias.
Cancer gene therapy.
2022 05; 29(5):519-532. doi:
10.1038/s41417-021-00329-1. [PMID: 33833412] - Jaume Capdevila, Arkadiy Klochikhin, Sophie Leboulleux, Pavel Isaev, Corin Badiu, Bruce Robinson, Brett G M Hughes, Bhumsuk Keam, Francis Parnis, Rossella Elisei, Pablo Gajate, Hui K Gan, Ellen Kapiteijn, Laura Locati, Milan Mangeshkar, Leonardo Faoro, Jolanta Krajewska, Barbara Jarzab. A Randomized, Double-Blind Noninferiority Study to Evaluate the Efficacy of the Cabozantinib Tablet at 60 mg Per Day Compared with the Cabozantinib Capsule at 140 mg Per Day in Patients with Progressive, Metastatic Medullary Thyroid Cancer.
Thyroid : official journal of the American Thyroid Association.
2022 05; 32(5):515-524. doi:
10.1089/thy.2022.0027. [PMID: 35403447] - Alessandro Rizzo, Veronica Mollica, Francesco Massari. Cabozantinib for Treatment of Brain Metastases in Patients With Renal Cell Carcinoma.
JAMA oncology.
2022 05; 8(5):783-784. doi:
10.1001/jamaoncol.2022.0049. [PMID: 35238907] - Binghao Zhao, Wenbin Ma. Cabozantinib for Treatment of Brain Metastases in Patients With Renal Cell Carcinoma.
JAMA oncology.
2022 05; 8(5):783. doi:
10.1001/jamaoncol.2022.0052. [PMID: 35238875] - Funda Meric-Bernstam, Nizar M Tannir, Othon Iliopoulos, Richard J Lee, Melinda L Telli, Alice C Fan, Angela DeMichele, Naomi B Haas, Manish R Patel, James J Harding, Martin H Voss, Taofeek K Owonikoko, Bradley Carthon, Ramaprasad Srinivasan, Johanna C Bendell, Yonchu Jenkins, Sam H Whiting, Keith Orford, Mark K Bennett, Todd M Bauer. Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I Trial.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2022 04; 28(8):1540-1548. doi:
10.1158/1078-0432.ccr-21-2972. [PMID: 35140121] - Lora Hamuro, Zheyi Hu, Julie Passarell, Heather Barcomb, Joshua Zhang, Shay Goldstein, Akintunde Bello, Amit Roy, Li Zhu. Exposure-Response Analysis to Support Nivolumab Once Every 4 Weeks Dosing in Combination with Cabozantinib in Renal Cell Carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2022 04; 28(8):1603-1613. doi:
10.1158/1078-0432.ccr-21-3149. [PMID: 34980597] - Hanlu Ye, Jingjing Yan, Qiong Wang, Hui Tian, Lei Zhou. The protective effects of cabozantinib against high glucose-induced damages in in vitro renal glomerular endothelial cells model via inhibition of early growth response-1 (Egr-1).
Bioengineered.
2022 04; 13(4):10605-10616. doi:
10.1080/21655979.2022.2063667. [PMID: 35441585] - Reyna Jones, Julianne Holleran, Robert A Parise, Michelle A Rudek, Jennifer Chan, Yujia Wen, Joga Gobburu, Lionel D Lewis, Jan H Beumer. Quantitation of Cabozantinib in Human Plasma by LC-MS/MS.
Journal of chromatographic science.
2022 Mar; 60(3):274-279. doi:
10.1093/chromsci/bmab090. [PMID: 34240176] - Stefanie D Krens, Nielka P van Erp, Stefanie L Groenland, Dirk Jan A R Moes, Sasja F Mulder, Ingrid M E Desar, Tom van der Hulle, Neeltje Steeghs, Carla M L van Herpen. Exposure-response analyses of cabozantinib in patients with metastatic renal cell cancer.
BMC cancer.
2022 Mar; 22(1):228. doi:
10.1186/s12885-022-09338-1. [PMID: 35236333] - Robin Kate Kelley, Rebecca Miksad, Irfan Cicin, YenHsun Chen, Heinz-Josef Klümpen, Stefano Kim, Zhong-Zhe Lin, Jillian Youkstetter, Saswati Hazra, Suvajit Sen, Ann-Lii Cheng, Anthony B El-Khoueiry, Tim Meyer, Ghassan K Abou-Alfa. Efficacy and safety of cabozantinib for patients with advanced hepatocellular carcinoma based on albumin-bilirubin grade.
British journal of cancer.
2022 03; 126(4):569-575. doi:
10.1038/s41416-021-01532-5. [PMID: 34621044] - Jingquan Jia, Lauren Howard, Yingmiao Liu, Mark D Starr, John C Brady, Donna Niedzwiecki, John H Strickler, Andrew B Nixon. Cabozantinib with or without Panitumumab for RAS wild-type metastatic colorectal cancer: impact of MET amplification on clinical outcomes and circulating biomarkers.
Cancer chemotherapy and pharmacology.
2022 Mar; 89(3):413-422. doi:
10.1007/s00280-022-04404-8. [PMID: 35171350] - Igor Richter, Alexandr Poprach, Anezka Zemankova, Tomas Buchler, Jiri Bartos, Vladimir Samal, Hana Studentova, Aneta Rozsypalova, Josef Dvorak, Ondrej Brom, Bohuslav Melichar. Patients with metastatic renal cell carcinoma treated with cabozantinib in the Czech Republic: analysis of four cancer centers.
Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia.
2022 Mar; 166(1):97-104. doi:
10.5507/bp.2020.055. [PMID: 33252116] - Laurence Albiges, Manuela Schmidinger, Naila Taguieva-Pioger, David Perol, Viktor Grünwald, Eric Guemas. CaboPoint: a phase II study of cabozantinib as second-line treatment in patients with metastatic renal cell carcinoma.
Future oncology (London, England).
2022 Mar; 18(8):915-926. doi:
10.2217/fon-2021-1006. [PMID: 34911359] - Anthony Markham. Cabozantinib plus Nivolumab: A Review in Advanced Renal Cell Carcinoma.
Targeted oncology.
2022 03; 17(2):193-201. doi:
10.1007/s11523-022-00866-1. [PMID: 35175500] - Thomas Denize, Subrina Farah, Alessia Cimadamore, Abdallah Flaifel, Emily Walton, Maura A Sticco-Ivins, Chris Labaki, David A Braun, Maxine Sun, Evelyn Wang, Wanling Xie, Toni K Choueiri, Sabina Signoretti. Biomarkers of Angiogenesis and Clinical Outcomes to Cabozantinib and Everolimus in Patients with Metastatic Renal Cell Carcinoma from the Phase III METEOR Trial.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2022 02; 28(4):748-755. doi:
10.1158/1078-0432.ccr-21-3088. [PMID: 34921022] - Dylan J Martini, Sean T Evans, Yuan Liu, Julie M Shabto, Ogul E Uner, T Anders Olsen, Jacqueline T Brown, Greta Anne Russler, Lauren Yantorni, Sarah Caulfield, Jamie M Goldman, Bassel Nazha, Wayne B Harris, Viraj A Master, Omer Kucuk, Bradley C Carthon, Mehmet Asim Bilen. Analysis of Toxicity and Clinical Outcomes in Full Versus Reduced Starting Dose Cabozantinib in Metastatic Renal Cell Carcinoma Patients.
Clinical genitourinary cancer.
2022 02; 20(1):53-59. doi:
10.1016/j.clgc.2021.11.004. [PMID: 34922840] - David Cella, Robert J Motzer, Cristina Suarez, Steven I Blum, Flavia Ejzykowicz, Melissa Hamilton, Joel F Wallace, Burcin Simsek, Joshua Zhang, Cristina Ivanescu, Andrea B Apolo, Toni K Choueiri. Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial.
The Lancet. Oncology.
2022 02; 23(2):292-303. doi:
10.1016/s1470-2045(21)00693-8. [PMID: 35032437] - Sebastiano Buti, Melissa Bersanelli, Giulia Mazzaschi, Carlo Cattrini, Matteo Brunelli, Massimo Di Maio. Can we identify a preferred first-line strategy for sarcomatoid renal cell carcinoma? A network meta-analysis.
Immunotherapy.
2022 02; 14(2):145-153. doi:
10.2217/imt-2021-0157. [PMID: 34806404] - Balaji Venugopal, Manon Pillai, Thomas Powles, Philip Savage, Agnieszka Michael, Kate Fife, Bhupinder Klair, Valerie Perrot, Bernadett Szabados. Early Clinical Experience with Cabozantinib for Advanced Renal Cell Carcinoma in the UK: Real-World Treatment Pathways and Clinical Outcomes.
Clinical genitourinary cancer.
2022 02; 20(1):94-94.e10. doi:
10.1016/j.clgc.2021.09.005. [PMID: 34802966] - Luigi Cerbone, Vincenzo Di Nunno, Lucia Carril Ajuria, Carolina Alves Costa Silva, Emeline Colomba, Annalisa Guida, Flore Salviat, Laure Hirsch, Axelle Benchimol-Zouari, Ronan Flippot, Bernard Escudier, Laurence Albiges. Activity of Systemic Treatments After Cabozantinib Failure in Advanced Metastatic Renal Cell Carcinoma.
Clinical genitourinary cancer.
2022 02; 20(1):80-87. doi:
10.1016/j.clgc.2021.09.001. [PMID: 34688544] - NULL. Title Not Available.
Aktuelle Urologie.
2022 02; 53(1):16-18. doi:
10.1055/a-1559-4893. [PMID: 35078256] - Bradley McGregor, Amir Mortazavi, Lisa Cordes, Cristina Salabao, Susan Vandlik, Andrea B Apolo. Management of adverse events associated with cabozantinib plus nivolumab in renal cell carcinoma: A review.
Cancer treatment reviews.
2022 Feb; 103(?):102333. doi:
10.1016/j.ctrv.2021.102333. [PMID: 35033866] - Stefanie D Krens, Wim van Boxtel, Maike J M Uijen, Frank G A Jansman, Ingrid M E Desar, Sasja F Mulder, Carla M L van Herpen, Nielka P van Erp. Exposure-toxicity relationship of cabozantinib in patients with renal cell cancer and salivary gland cancer.
International journal of cancer.
2022 01; 150(2):308-316. doi:
10.1002/ijc.33797. [PMID: 34494665] - Alessia Mennitto, Emma Zattarin, Massimo Di Maio, Davide Bimbatti, Ugo De Giorgi, Sebastiano Buti, Daniele Santini, Chiara Casadei, Mariella Sorarù, Carlo Messina, Claudia Mucciarini, Giuseppe Di Lorenzo, Giandomenico Roviello, Consuelo Buttigliero, Marco Stellato, Pierangela Sepe, Melanie Claps, Valentina Guadalupi, Arianna Ottini, Sandro Pignata, Filippo G De Braud, Elena Verzoni, Giuseppe Procopio. Cabozantinib beyond progression improves survival in advanced renal cell carcinoma patients: the CABEYOND study (Meet-URO 21).
Expert review of anticancer therapy.
2022 Jan; 22(1):115-121. doi:
10.1080/14737140.2022.2002688. [PMID: 34738499] - Manuela Schmidinger, Robert J Motzer, Frederic Rolland, Michael Staehler, Michael Rink, Margitta Retz, Tibor Csoszi, John A McCaffrey, Ugo De Giorgi, Claudia Caserta, Ignacio Duran, Fawzi Benzaghou, Douglas O Clary, Laurence Albiges, Toni K Choueiri, Nizar M Tannir. Analysis by region of outcomes for patients with advanced renal cell carcinoma treated with cabozantinib or everolimus: a sub-analysis of the METEOR study.
Acta oncologica (Stockholm, Sweden).
2022 Jan; 61(1):52-57. doi:
10.1080/0284186x.2021.1995041. [PMID: 34736367] - Matteo Santoni, Alessandro Rizzo, Veronica Mollica, Matteo Rosellini, Andrea Marchetti, Benedetta Fragomeno, Nicola Battelli, Francesco Massari. Pembrolizumab plus lenvatinib or axitinib compared to nivolumab plus ipilimumab or cabozantinib in advanced renal cell carcinoma: a number needed to treat analysis.
Expert review of pharmacoeconomics & outcomes research.
2022 Jan; 22(1):45-51. doi:
10.1080/14737167.2021.1937130. [PMID: 34058953] - Luis Meza, Jasnoor Malhotra, Crystal Favorito, Sumanta K Pal. Cabozantinib plus immunotherapy combinations in metastatic renal cell and urothelial carcinoma.
Future oncology (London, England).
2022 Jan; 18(1):21-33. doi:
10.2217/fon-2021-0570. [PMID: 34766841] - Keon Young Park, Hunter O Hefti, Peng Liu, Karina M Lugo-Cintrón, Sheena C Kerr, David J Beebe. Immune cell mediated cabozantinib resistance for patients with renal cell carcinoma.
Integrative biology : quantitative biosciences from nano to macro.
2021 12; 13(11):259-268. doi:
10.1093/intbio/zyab018. [PMID: 34931665] - Laure Hirsch, Nieves Martinez Chanza, Subrina Farah, Wanling Xie, Ronan Flippot, David A Braun, Nityam Rathi, Jonathan Thouvenin, Katharine A Collier, Emmanuel Seront, Guillermo de Velasco, Hannah Dzimitrowicz, Benoit Beuselinck, Wenxin Xu, I Alex Bowman, Elaine T Lam, Bashar Abuqayas, Mehmet Asim Bilen, Andreas Varkaris, Yousef Zakharia, Michael R Harrison, Amir Mortazavi, Philippe Barthélémy, Neeraj Agarwal, Rana R McKay, Priscilla K Brastianos, Katherine M Krajewski, Laurence Albigès, Lauren C Harshman, Toni K Choueiri. Clinical Activity and Safety of Cabozantinib for Brain Metastases in Patients With Renal Cell Carcinoma.
JAMA oncology.
2021 Dec; 7(12):1815-1823. doi:
10.1001/jamaoncol.2021.4544. [PMID: 34673916] - Weiting Liao, Wanting Lei, Mingyang Feng, Yang Yang, Qiuji Wu, Kexun Zhou, Liangliang Bai, Feng Wen, Qiu Li. Cost-Effectiveness Analysis of First-Line Nivolumab Plus Cabozantinib for Advanced Renal Cell Carcinoma in the United States.
Advances in therapy.
2021 12; 38(12):5662-5670. doi:
10.1007/s12325-021-01926-0. [PMID: 34664194] - Andrea Marchetti, Matteo Rosellini, Alessandro Rizzo, Veronica Mollica, Nicola Battelli, Francesco Massari, Matteo Santoni. An up-to-date evaluation of cabozantinib for the treatment of renal cell carcinoma.
Expert opinion on pharmacotherapy.
2021 Dec; 22(17):2323-2336. doi:
10.1080/14656566.2021.1959548. [PMID: 34405738] - Mariangela Massaccesi, Luca Boldrini, Angela Romano, Ernesto Rossi, Giovanni Schinzari, Elisabetta Lepre, Maria Antonietta Gambacorta, Vincenzo Valentini. Unconventional radiotherapy to enhance immunotherapy efficacy in bulky tumors: a case report.
Immunotherapy.
2021 12; 13(18):1457-1463. doi:
10.2217/imt-2020-0289. [PMID: 34664999] - Raffaele Ratta, Elena Verzoni, Alessia Mennitto, Francesco Pantano, Antonia Martinetti, Alessandra Raimondi, Pierangela Sepe, Elisa Sottotetti, Roberta Mennitto, Daniele Morelli, Daniele Santini, Filippo G de Braud, Giuseppe Procopio. Effects of cabozantinib on bone turnover markers in real-world metastatic renal cell carcinoma.
Tumori.
2021 Dec; 107(6):542-549. doi:
10.1177/0300891620969817. [PMID: 33153416] - L Cerbone, D Combarel, A Geraud, E Auclin, S Foulon, C Alves Costa Silva, E Colomba, L Carril, L Derosa, R Flippot, O Mir, N Khoudour, B Blanchet, B Escudier, A Paci, L Albiges. Association of cabozantinib pharmacokinetics, progression and toxicity in metastatic renal cell carcinoma patients: results from a pharmacokinetics/pharmacodynamics study.
ESMO open.
2021 12; 6(6):100312. doi:
10.1016/j.esmoop.2021.100312. [PMID: 34864351] - Cecilia Nasso, Roberto Sabbatini, Cinzia Baldessari, Massimo Dominici, Maria Giuseppa Vitale. Long progression-free survival with cabozantinib in a heavily pretreated patient with metastatic renal cell carcinoma: a case report.
Tumori.
2021 Dec; 107(6):NP33-NP36. doi:
10.1177/0300891621990732. [PMID: 33526000] - Sumanta K Pal, Bradley McGregor, Cristina Suárez, Che-Kai Tsao, William Kelly, Ulka Vaishampayan, Lance Pagliaro, Benjamin L Maughan, Yohann Loriot, Daniel Castellano, Sandy Srinivas, Rana R McKay, Robert Dreicer, Thomas Hutson, Sarita Dubey, Scott Werneke, Ashok Panneerselvam, Dominic Curran, Christian Scheffold, Toni K Choueiri, Neeraj Agarwal. Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2021 11; 39(33):3725-3736. doi:
10.1200/jco.21.00939. [PMID: 34491815] - Natacha Naoun, Yann-Alexandre Vano. [New EMA approval: Nivolumab plus Cabozantinib for advanced renal clear cell carcinoma].
Bulletin du cancer.
2021 Nov; 108(11):991-993. doi:
10.1016/j.bulcan.2021.05.005. [PMID: 34538614] - Maria Giuseppa Vitale, Cecilia Nasso, Marco Oltrecolli, Cinzia Baldessari, Martina Fanelli, Massimo Dominici, Roberto Sabbatini. Cabozantinib and nivolumab as first-line treatment in advanced renal cell carcinoma.
Expert review of anticancer therapy.
2021 11; 21(11):1183-1192. doi:
10.1080/14737140.2021.1971519. [PMID: 34424125] - Sebastian Zimmermann, Max Kurlbaum, Stefanie Mayer, Martin Fassnacht, Matthias Kroiss, Oliver Scherf-Clavel. Simulation-Based Interpretation of Therapeutically Monitored Cabozantinib Plasma Concentration in Advanced Adrenocortical Carcinoma with Hemodialysis.
Therapeutic drug monitoring.
2021 10; 43(5):706-711. doi:
10.1097/ftd.0000000000000905. [PMID: 34001696] - Yuka Aimono, Tatsunori Ogawa, Takahiro Yagisawa, Eri Ogawa, Shunichi Suzuki, Yoshiko Saito, Sakiko Kikuchi, Masakazu Tsutsumi, Akihiro Tamura. [Side Effect Management in the Early Stages of Cabozantinib Administration].
Gan to kagaku ryoho. Cancer & chemotherapy.
2021 Oct; 48(10):1269-1271. doi:
NULL. [PMID: 34657061] - Matteo Santoni, Francesco Massari, Enrique Grande, Giuseppe Procopio, Marc R Matrana, Mimma Rizzo, Ugo De Giorgi, Umberto Basso, Michele Milella, Roberto Iacovelli, Gaetano Aurilio, Lorena Incorvaia, Sebastiano Buti, Orazio Caffo, Giuseppe Fornarini, Francesco Carrozza, Veronica Mollica, Alessandro Rizzo, Fady Farag, Javier Molina-Cerrillo, Nicola Battelli. Cabozantinib in Pretreated Patients with Metastatic Renal Cell Carcinoma with Sarcomatoid Differentiation: A Real-World Study.
Targeted oncology.
2021 09; 16(5):625-632. doi:
10.1007/s11523-021-00828-z. [PMID: 34338966] - Matteo Santoni, Roberto Iacovelli, Valentina Colonna, Stephan Klinz, Giorgio Mauri, Marianna Nuti. Antitumor effects of the multi-target tyrosine kinase inhibitor cabozantinib: a comprehensive review of the preclinical evidence.
Expert review of anticancer therapy.
2021 09; 21(9):1029-1054. doi:
10.1080/14737140.2021.1919090. [PMID: 34445927] - Eddy Lilly, Julien Sarkis. The nivolumab/cabozantinib combination and the future of doublets in advanced renal cell cancer treatment.
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.
2021 Sep; 27(6):1553-1554. doi:
10.1177/10781552211027942. [PMID: 34162248] - Won Jin Ho, Qingfeng Zhu, Jennifer Durham, Aleksandra Popovic, Stephanie Xavier, James Leatherman, Aditya Mohan, Guanglan Mo, Shu Zhang, Nicole Gross, Soren Charmsaz, Dongxia Lin, Derek Quong, Brad Wilt, Ihab R Kamel, Matthew Weiss, Benjamin Philosophe, Richard Burkhart, William R Burns, Chris Shubert, Aslam Ejaz, Jin He, Atul Deshpande, Ludmila Danilova, Genevieve Stein-O'Brien, Elizabeth A Sugar, Daniel A Laheru, Robert A Anders, Elana J Fertig, Elizabeth M Jaffee, Mark Yarchoan. Neoadjuvant Cabozantinib and Nivolumab Converts Locally Advanced HCC into Resectable Disease with Enhanced Antitumor Immunity.
Nature cancer.
2021 09; 2(9):891-903. doi:
10.1038/s43018-021-00234-4. [PMID: 34796337] - Thomas Powles, Toni K Choueiri, Robert J Motzer, Eric Jonasch, Sumanta Pal, Nizar M Tannir, Sabina Signoretti, Rajesh Kaldate, Christian Scheffold, Evelyn Wang, Dana T Aftab, Bernard Escudier, Daniel J George. Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma.
BMC cancer.
2021 Aug; 21(1):904. doi:
10.1186/s12885-021-08630-w. [PMID: 34364385] - Viktor Grünwald, Boris Hadaschik. Re: Nivolumab plus Cabozantinib Versus Sunitinib for Advanced Renal-cell Carcinoma.
European urology.
2021 08; 80(2):256-257. doi:
10.1016/j.eururo.2021.04.039. [PMID: 33992475] - Siin Kim, Sola Han, Hyungtae Kim, Hae Sun Suh. Cost-Effectiveness and Value of Information of Cabozantinib Treatment for Patients with Advanced Renal Cell Carcinoma After Failure of Prior Therapy in South Korea.
Applied health economics and health policy.
2021 07; 19(4):545-555. doi:
10.1007/s40258-021-00640-w. [PMID: 33651367] - Guofan Xu, Yang Lu. Progression of Cabozantinib-Related Osteonecrosis Mimicking Metastases on Bone Scan.
Clinical nuclear medicine.
2021 Jul; 46(7):592-594. doi:
10.1097/rlu.0000000000003522. [PMID: 33577198] - G S Coltart, J E Sutton, H J Roche, M P Sommerlad, S J Crabb, E Healy. Cutaneous leucocytoclastic vasculitis secondary to cabozantinib therapy for renal cell carcinoma.
Clinical and experimental dermatology.
2021 Jun; 46(4):739-740. doi:
10.1111/ced.14541. [PMID: 33332666] - Hui-Wen Lue, Daniel S Derrick, Soumya Rao, Ahna Van Gaest, Larry Cheng, Jennifer Podolak, Samantha Lawson, Changhui Xue, Devin Garg, Ralph White, Christopher W Ryan, Justin M Drake, Anna Ritz, Laura M Heiser, George V Thomas. Cabozantinib and dasatinib synergize to induce tumor regression in non-clear cell renal cell carcinoma.
Cell reports. Medicine.
2021 05; 2(5):100267. doi:
10.1016/j.xcrm.2021.100267. [PMID: 34095877] - Arianna E Azari, Richard Stratton, Animesh Singh. First case of hemophagocytic lymphohistiocytosis secondary to cabozantinib with checkpoint inhibitors.
Rheumatology (Oxford, England).
2021 05; 60(5):e167-e168. doi:
10.1093/rheumatology/keaa750. [PMID: 33280022] - Hidekazu Tachibana, Yudai Ishiyama, Maki Yoshino, Kaori Yamashita, Daisuke Toki, Tsunenori Kondo. Efficacy of Cabozantinib in Metastatic Papillary Renal Cell Carcinoma Following Ineffective Treatment With Initial Therapy of Nivolumab and Ipilimumab.
In vivo (Athens, Greece).
2021 May; 35(3):1743-1747. doi:
10.21873/invivo.12433. [PMID: 33910858] - Elie Rassy, Luigi Cerbone, Edouard Auclin, Axelle Benchimoll-Zouari, Ronan Flippot, Carolina Alves Costa Silva, Emeline Colomba, Arthur Geraud, Annalisa Guida, Olivier Mir, David Combarel, Angelo Paci, Bernard Escudier, Laurence Albiges. The Effect of Concomitant Proton Pump Inhibitor and Cabozantinib on the Outcomes of Patients with Metastatic Renal Cell Carcinoma.
The oncologist.
2021 05; 26(5):389-396. doi:
10.1002/onco.13711. [PMID: 33554383] - Jörg Trojan, Patrick Mollon, Bruno Daniele, Florence Marteau, Lidia Martín, Yuxin Li, Qing Xu, Fabio Piscaglia, Renata Zaucha, Debashis Sarker, Ho Yeong Lim, Marino Venerito. Comparative Efficacy of Cabozantinib and Ramucirumab After Sorafenib for Patients with Hepatocellular Carcinoma and Alpha-fetoprotein ≥ 400 ng/mL: A Matching-Adjusted Indirect Comparison.
Advances in therapy.
2021 05; 38(5):2472-2490. doi:
10.1007/s12325-021-01700-2. [PMID: 33822328] - Andrew L Laccetti, Benjamin Garmezy, Lianchun Xiao, Minas Economides, Aradhana Venkatesan, Jianjun Gao, Eric Jonasch, Paul Corn, Amado Zurita-Saavedra, Landon C Brown, Chester Kao, Emily N Kinsey, Rajan T Gupta, Michael R Harrison, Andrew J Armstrong, Daniel J George, Nizar Tannir, Pavlos Msaouel, Amishi Shah, Tian Zhang, Matthew T Campbell. Combination antiangiogenic tyrosine kinase inhibition and anti-PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes.
Cancer medicine.
2021 04; 10(7):2341-2349. doi:
10.1002/cam4.3812. [PMID: 33650321] - Toni K Choueiri, Thomas Powles, Mauricio Burotto, Bernard Escudier, Maria T Bourlon, Bogdan Zurawski, Victor M Oyervides Juárez, James J Hsieh, Umberto Basso, Amishi Y Shah, Cristina Suárez, Alketa Hamzaj, Jeffrey C Goh, Carlos Barrios, Martin Richardet, Camillo Porta, Rubén Kowalyszyn, Juan P Feregrino, Jakub Żołnierek, David Pook, Elizabeth R Kessler, Yoshihiko Tomita, Ryuichi Mizuno, Jens Bedke, Joshua Zhang, Matthew A Maurer, Burcin Simsek, Flavia Ejzykowicz, Gisela M Schwab, Andrea B Apolo, Robert J Motzer. Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
The New England journal of medicine.
2021 03; 384(9):829-841. doi:
10.1056/nejmoa2026982. [PMID: 33657295] - Daniele Santini, Marco Stellato, Ugo De Giorgi, Francesco Pantano, Delia De Lisi, Chiara Casadei, Marco Maruzzo, Davide Bimbatti, Emanuele Naglieri, Sebastiano Buti, Melissa Bersanelli, Rocco De Vivo, Giuseppe Di Lorenzo, Andrea Sbrana, Elena Verzoni, Mariella Soraru', Giuseppe Fornarini, Claudia Mucciarini, Francesco Grillone, Enrico Mini, Francesca Vignani, Laura Attademo, Sandro Pignata, Giuseppe Procopio. Clinical Outcomes of Metastatic Renal Carcinoma Following Disease Progression to Programmed Death (PD)-1 or PD-L1 Inhibitors (IO): A Meet-URO Group Real World Study (Meet-Uro 7).
American journal of clinical oncology.
2021 03; 44(3):121-125. doi:
10.1097/coc.0000000000000791. [PMID: 33617179] - Julien Sarkis, Nour Khalil, Marwan Alkassis. Combination of cabozantinib and immune checkpoint inhibitors in advanced renal cell carcinoma: update from the European Society for Medical Oncology 2020.
Future oncology (London, England).
2021 Mar; 17(9):991-992. doi:
10.2217/fon-2020-1061. [PMID: 33533650] - T Powles. Recent eUpdate to the ESMO Clinical Practice Guidelines on renal cell carcinoma on cabozantinib and nivolumab for first-line clear cell renal cancer: Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Annals of oncology : official journal of the European Society for Medical Oncology.
2021 03; 32(3):422-423. doi:
10.1016/j.annonc.2020.11.016. [PMID: 33271289] - Chester Kao, Daniel J George, Tian Zhang. An Illustrative Case of Combination Cabozantinib/Nivolumab for Progressive Metastatic Renal Cell Carcinoma (mRCC).
The oncologist.
2021 03; 26(3):e508-e511. doi:
10.1002/onco.13617. [PMID: 33251710] - Jens Bedke, Laurence Albiges, Umberto Capitanio, Rachel H Giles, Milan Hora, Thomas B Lam, Börje Ljungberg, Lorenzo Marconi, Tobias Klatte, Alessandro Volpe, Yasmin Abu-Ghanem, Saeed Dabestani, Sergio Fernández-Pello, Fabian Hofmann, Teele Kuusk, Rana Tahbaz, Thomas Powles, Axel Bex. Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naïve Metastatic Clear-Cell Renal Cell Carcinoma.
European urology.
2021 03; 79(3):339-342. doi:
10.1016/j.eururo.2020.12.005. [PMID: 33357997] - Delphine Borchiellini, Philippe Barthélémy. Cabozantinib: a new first-line option for papillary renal cell carcinoma?.
Lancet (London, England).
2021 02; 397(10275):645-647. doi:
10.1016/s0140-6736(21)00316-0. [PMID: 33592177] - Sumanta K Pal, Catherine Tangen, Ian M Thompson, Naomi Balzer-Haas, Daniel J George, Daniel Y C Heng, Brian Shuch, Mark Stein, Maria Tretiakova, Peter Humphrey, Adebowale Adeniran, Vivek Narayan, Georg A Bjarnason, Ulka Vaishampayan, Ajjai Alva, Tian Zhang, Scott Cole, Melissa Plets, John Wright, Primo N Lara. A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial.
Lancet (London, England).
2021 02; 397(10275):695-703. doi:
10.1016/s0140-6736(21)00152-5. [PMID: 33592176] - Ji Haeng Heo, Chanhyun Park, Somraj Ghosh, Sun-Kyeong Park, Marko Zivkovic, Karen L Rascati. A network meta-analysis of efficacy and safety of first-line and second-line therapies for the management of metastatic renal cell carcinoma.
Journal of clinical pharmacy and therapeutics.
2021 Feb; 46(1):35-49. doi:
10.1111/jcpt.13282. [PMID: 33112003] - Chun Loo Gan, Shaan Dudani, J Connor Wells, Frede Donskov, Sumanta K Pal, Nazli Dizman, Nityam Rathi, Benoit Beuselinck, Flora Yan, Aly-Khan A Lalani, Aaron Hansen, Bernadett Szabados, Guillermo de Velasco, Ben Tran, Jae Lyun Lee, Ulka N Vaishampayan, Georg A Bjarnason, Mathushan Subasri, Toni K Choueiri, Daniel Y C Heng. Cabozantinib real-world effectiveness in the first-through fourth-line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Cancer medicine.
2021 02; 10(4):1212-1221. doi:
10.1002/cam4.3717. [PMID: 33463028] - Vegard Torp Lien, Sofie Celen, Syed Nuruddin, Bala Attili, Gilles Doumont, Gaetan Van Simaeys, Guy Bormans, Jo Klaveness, Dag Erlend Olberg. Preclinical evaluation of [18F]cabozantinib as a PET imaging agent in a prostate cancer mouse model.
Nuclear medicine and biology.
2021 02; 93(?):74-80. doi:
10.1016/j.nucmedbio.2020.12.002. [PMID: 33422771] - Ruo-Yan Qin, Ling-Shuang Liu, Hui-Yong Zhang, Cheng-Hua Lu, Xiao-Yan Guo, Ling-Yue Zhang, Xin-Bei Yuan, Hong-Hao Xue. Responses to crizotinib and cabozantinib in patient with lung adenocarcinoma harboring mesenchymal-epithelial transition factor exon 14 skipping mutation: A case report.
Medicine.
2021 Jan; 100(4):e24300. doi:
10.1097/md.0000000000024300. [PMID: 33530219] - David H Aggen, Casey R Ager, Aleksandar Z Obradovic, Nivedita Chowdhury, Ali Ghasemzadeh, Wendy Mao, Matthew G Chaimowitz, Zoila A Lopez-Bujanda, Catherine S Spina, Jessica E Hawley, Matthew C Dallos, Cheng Zhang, Vinson Wang, Hu Li, Xinzheng V Guo, Charles G Drake. Blocking IL1 Beta Promotes Tumor Regression and Remodeling of the Myeloid Compartment in a Renal Cell Carcinoma Model: Multidimensional Analyses.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2021 01; 27(2):608-621. doi:
10.1158/1078-0432.ccr-20-1610. [PMID: 33148676] - Ethan Emberley, Alison Pan, Jason Chen, Rosalyn Dang, Matt Gross, Tony Huang, Weiqun Li, Andrew MacKinnon, Devansh Singh, Natalija Sotirovska, Susanne M Steggerda, Tracy Wang, Francesco Parlati. The glutaminase inhibitor telaglenastat enhances the antitumor activity of signal transduction inhibitors everolimus and cabozantinib in models of renal cell carcinoma.
PloS one.
2021; 16(11):e0259241. doi:
10.1371/journal.pone.0259241. [PMID: 34731180] - Tsuyoshi Osaka, Naoya Yamaguchi, Takahito Hara. [Pharmacological properties and clinical outcomes of the anti-cancer drug, cabozantinib (CABOMETYX®)].
Nihon yakurigaku zasshi. Folia pharmacologica Japonica.
2021; 156(5):303-311. doi:
10.1254/fpj.21045. [PMID: 34470936] - I- Richter, A Poprach, A Zemánková, T Büchler, J Bartoš, V Šámal, H Študentová, A Rozsypalová, J Dvořák, O Brom, B Melichar. Cabozantinib in the treatment of metastatic renal cell carcinoma - final data analysis from four oncology centers in the Czech Republic.
Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti.
2021; 34(5):392-400. doi:
10.48095/ccko2021392. [PMID: 34915708] - V Cappagli, D Moriconi, A G Bonadio, D Giannese, Gaetano La Manna, M Francesca Egidi, G Comai, G Vischini, V Bottici, R Elisei, D Viola. Proteinuria is a late-onset adverse event in patients treated with cabozantinib.
Journal of endocrinological investigation.
2021 Jan; 44(1):95-103. doi:
10.1007/s40618-020-01272-y. [PMID: 32363491] - Dylan J Martini, Meredith R Kline, Yuan Liu, Julie M Shabto, Bradley C Carthon, Greta Anne Russler, Lauren Yantorni, Emilie Elise Hitron, Sarah Caulfield, Jamie M Goldman, Wayne B Harris, Omer Kucuk, Viraj A Master, Mehmet Asim Bilen. Novel risk scoring system for metastatic renal cell carcinoma patients treated with cabozantinib.
Cancer treatment and research communications.
2021; 28(?):100393. doi:
10.1016/j.ctarc.2021.100393. [PMID: 34029879] - Ronald C Chen, Toni K Choueiri, Marion Feuilly, Jie Meng, Johanna Lister, Florence Marteau, Aaron D Falchook, Michael J Morris, Daniel J George, Darren R Feldman. Quality-adjusted survival with first-line cabozantinib or sunitinib for advanced renal cell carcinoma in the CABOSUN randomized clinical trial (Alliance).
Cancer.
2020 12; 126(24):5311-5318. doi:
10.1002/cncr.33169. [PMID: 33022096] - Jeanny B Aragon-Ching, Ravi A Madan. Life under the CABOSUN: Cabozantinib improves quality-adjusted survival in comparison with sunitinib.
Cancer.
2020 12; 126(24):5210-5212. doi:
10.1002/cncr.33168. [PMID: 33022092] - Shawn David Ellis, Alison Meikle, Wassim Al-Salti, Georges Sinclair. Rare case of clear cell renal cell carcinoma presenting as a unilateral tonsil lesion.
BMJ case reports.
2020 Dec; 13(12):. doi:
10.1136/bcr-2020-237941. [PMID: 33303501] - Arya Mariam Roy, Andrew Briggler, Danielle Tippit, Kellen Dawson, Rashmi Verma. Neoadjuvant Cabozantinib in Renal-Cell Carcinoma: A Brief Review.
Clinical genitourinary cancer.
2020 12; 18(6):e688-e691. doi:
10.1016/j.clgc.2020.04.003. [PMID: 32660880] - H M N Chen, M Morris, P M Manders. Cabozantinib as the causative agent of high-grade fever in a patient with a background of metastatic clear cell renal cell carcinoma: a case report.
Journal of medical case reports.
2020 Nov; 14(1):225. doi:
10.1186/s13256-020-02560-0. [PMID: 33213524] - Yoshihiko Tomita, Katsunori Tatsugami, Noboru Nakaigawa, Takahiro Osawa, Mototsugu Oya, Hiroomi Kanayama, Chihiro Nakayama Kondoh, Naoto Sassa, Kazuo Nishimura, Masahiro Nozawa, Naoya Masumori, Yasuhide Miyoshi, Shingo Kuroda, Shingo Tanaka, Akiko Kimura, Satoshi Tamada. Cabozantinib in advanced renal cell carcinoma: A phase II, open-label, single-arm study of Japanese patients.
International journal of urology : official journal of the Japanese Urological Association.
2020 11; 27(11):952-959. doi:
10.1111/iju.14329. [PMID: 32789967] - Robin Kate Kelley, Tim Meyer, Lorenza Rimassa, Philippe Merle, Joong-Won Park, Thomas Yau, Stephen L Chan, Jean-Frederic Blanc, Vincent C Tam, Albert Tran, Vincenzo Dadduzio, David W Markby, Rajesh Kaldate, Ann-Lii Cheng, Anthony B El-Khoueiry, Ghassan K Abou-Alfa. Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2020 09; 26(18):4795-4804. doi:
10.1158/1078-0432.ccr-19-3884. [PMID: 32636319] - Daniel Castellano, Jose Pablo Maroto, Fawzi Benzaghou, Naila Taguieva, Linh Nguyen, Douglas O Clary, Eric Jonasch. Exposure-response modeling of cabozantinib in patients with renal cell carcinoma: Implications for patient care.
Cancer treatment reviews.
2020 Sep; 89(?):102062. doi:
10.1016/j.ctrv.2020.102062. [PMID: 32659623] - Marina Deuker, Felix K H Chun, Pierre I Karakiewicz. Second-line tyrosine kinase inhibitor-therapy after immunotherapy-failure.
Current opinion in supportive and palliative care.
2020 09; 14(3):276-285. doi:
10.1097/spc.0000000000000519. [PMID: 32769619] - Amrita Goyal, Audrey A Jacobsen, Daniel O'Leary, Allison Watson, Sharon Luikart, Kevin J Gaddis. Hand-foot skin reaction with primarily dorsal involvement in a patient with metastatic renal cell carcinoma on cabozantinib.
Dermatology online journal.
2020 Aug; 26(8):. doi:
NULL. [PMID: 32941722]